The Formidable Challenge of Controlling High Mannose-Type N-Glycans in Therapeutic mAbs

生物制药 糖基化 聚糖 单克隆抗体 甘露糖 生物仿制药 化学 抗体 计算生物学 关键质量属性 生物 药理学 生物化学 免疫学 糖蛋白 生物技术 物理化学 粒径
作者
Renato Mastrangeli,Maria Concetta Audino,Wolf Palinsky,Hervé Broly,Horst Bierau
出处
期刊:Trends in Biotechnology [Elsevier BV]
卷期号:38 (10): 1154-1168 被引量:49
标识
DOI:10.1016/j.tibtech.2020.05.009
摘要

mAbs are currently the prime focus in biopharmaceutical drug development. Glycosylation is a critical quality attribute for mAbs because their clinical efficacy and safety are significantly affected by their glycosylation profile, which is generally heterogeneous, profoundly dependent on the manufacturing process, and thus prone to variations depending on cell culture conditions. As opposed to endogenous IgGs, marketed therapeutic mAbs contain higher levels of high mannose glycans, which can affect efficacy, pharmacokinetics, and stability. Current trends in biopharmaceutical manufacturing, such as process intensification and the rise of biosimilars, emphasize the need for a thorough understanding of the cellular processes, as well as the biotechnical process aspects that govern the production of high mannose-type N-glycans, in order to establish robust manufacturing processes. The clinical efficacy and safety of therapeutic monoclonal antibodies (mAbs) are significantly affected by their Fc-glycosylation profile. High mannose-type N-glycans (HM) affect efficacy (in terms of antibody-dependent cell cytotoxicity), pharmacokinetics, and stability. While in endogenous IgGs the HM levels are very low, they are significantly higher in marketed therapeutic mAbs. In order to meet the demands for late-phase clinical trial and market supply, process intensification is required. Since glycosylation profiles are sensitive to process variations and changes, controlling HM levels in robust manufacturing processes presents a formidable challenge and requires a thorough understanding of the cellular processes as well as the biotechnical aspects that govern the production of HM glycans. The clinical efficacy and safety of therapeutic monoclonal antibodies (mAbs) are significantly affected by their Fc-glycosylation profile. High mannose-type N-glycans (HM) affect efficacy (in terms of antibody-dependent cell cytotoxicity), pharmacokinetics, and stability. While in endogenous IgGs the HM levels are very low, they are significantly higher in marketed therapeutic mAbs. In order to meet the demands for late-phase clinical trial and market supply, process intensification is required. Since glycosylation profiles are sensitive to process variations and changes, controlling HM levels in robust manufacturing processes presents a formidable challenge and requires a thorough understanding of the cellular processes as well as the biotechnical aspects that govern the production of HM glycans. a mechanism of antibody-mediated target cell destruction where an immune cell lyses a target cell. a class of biopharmaceutical drugs composed of an antibody linked to a cytotoxic payload. a biopharmaceutical that is highly similar, but not identical, to a licensed medicinal product (‘originator’). a family of endocytic receptors that bind through carbohydrate-recognition domains (CRDs). Type I CLRs are calcium-dependent and have multiple CRDs [e.g., macrophage mannose receptor (MR)]. Type II CLRs contain a single CRD and can be either calcium-dependent, like Dectin 2 and DC-SIGN, or calcium-independent. a mechanism by which antibody-coated target cells, after binding to C1q, are destroyed through activation of the classical complement pathway. a continuous membrane system involved in the synthesis, folding, modification, quality control, and transport of proteins. also called CD16, binds to the Fc of IgG antibodies and activates ADCC. the fragment crystallizable region consists of a paired set of antibody heavy chain domains that bear the highly conserved N-glycosylation sites. It interacts with cell surface receptors responsible for the effector functions. a cell culture process with continuous or intermittent addition of nutrients to control the metabolic activity. The product remains in the bioreactor until the end of the run. Fc-fusion proteins are composed of the Fc domain of IgG genetically linked to another protein of interest. antibodies that consist entirely of human sequences. the attachment of an oligosaccharide structure, also referred to as glycan, to the asparagine (Asn) residue within the Asn–X–Ser/Thr consensus sequence. The N-glycosylation profile refers to the qualitative and quantitative composition of a mixture of structurally different glycans (complex-, hybrid-, and high mannose-type N-glycans). enzymes that catalyze the transfer of glycosyl groups from a nucleotide donor sugar to a substrate acceptor. intermediate glycoforms of the glycosylation pathway. The general term refers to glycans comprising between five and nine mannose residues. antibodies with sequences engineered to increase the resemblance with human antibodies, which, however, retain a low percentage of murine sequence regions. a modified fed-batch procedure in which a perfusion culture is utilized to inoculate the production bioreactor at a very high cell density in order to increase productivity. high mannose-type N-glycans containing five, six, seven, eight, or nine mannose residues, respectively. serum protein that, upon binding to bacterial carbohydrate, activates lectin-complement pathway. a series of unit operations required to produce the final product. For biotherapeutics, this includes the cell culturing, purification, formulation, as well as fill-&-finish processes. a group of molecules comprising nucleotides linked to sugars, which act as glycosyl donors in glycosylation reactions [e.g., uridine diphosphate–N-acetylglucosamine (UDP–GlcNAc) as the donor of N-acetyl glucosamine]. the concentration of osmotically active particles in a solution. It is an important parameter for intracellular ion homeostasis in cell culture. a perfusion cell culture process involves the constant feeding of fresh media and removal of spent media and product.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被陌陌采纳,获得10
刚刚
我是老大的应助被jia采纳,获得10
1秒前
piupiu完成签到,获得积分10
2秒前
zzz完成签到,获得积分10
2秒前
秋风的应助被英勇青烟采纳,获得10
2秒前
2秒前
3秒前
4秒前
4秒前
weiwei发布了新的文献求助10
4秒前
岚风完成签到,获得积分10
5秒前
初景发布了新的文献求助10
5秒前
鲁酷发布了新的文献求助10
5秒前
科研通AI65的应助被牧百川采纳,获得10
6秒前
6秒前
打打的应助被旺旺采纳,获得10
6秒前
溪秋白发布了新的文献求助10
7秒前
汉堡包的应助被跳跃靖采纳,获得10
7秒前
7秒前
beyfish发布了新的文献求助10
8秒前
刘哈哈完成签到,获得积分10
8秒前
Hello的应助被风格的好的采纳,获得10
8秒前
8秒前
CipherSage的应助被蔡莹采纳,获得10
9秒前
十一完成签到,获得积分10
9秒前
希音发布了新的文献求助30
10秒前
10秒前
黑猫发布了新的文献求助10
10秒前
852的应助被小茗同学采纳,获得10
11秒前
鲁酷完成签到,获得积分10
11秒前
sunidea发布了新的文献求助10
11秒前
CHEN完成签到 ,获得积分10
12秒前
12秒前
12秒前
溪秋白完成签到,获得积分10
13秒前
秋风的应助被pengyang采纳,获得20
13秒前
Corundum发布了新的文献求助10
15秒前
太阳完成签到,获得积分10
15秒前
灯儿发布了新的文献求助10
15秒前
zbbrainbow完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183403
求助须知:如何正确求助?哪些是违规求助? 9572654
关于积分的说明 21826992
捐赠科研通 7780463
什么是DOI,文献DOI怎么找? 3434008
关于科研通互助平台的介绍 2558183
邀请新用户注册赠送积分活动 2480337